Profile data is unavailable for this security.
About the company
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
- Revenue in USD (TTM)0.00
- Net income in USD-99.86m
- Incorporated2006
- Employees121.00
- LocationAdverum Biotechnologies Inc100 Cardinal WayREDWOOD CITY 94063United StatesUSA
- Phone+1 (650) 649-1004
- Fax+1 (650) 329-8151
- Websitehttps://adverum.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc | 48.89m | 2.74m | 144.73m | 36.00 | 135.99 | -- | 52.92 | 2.96 | 0.0389 | 0.0389 | 1.75 | -0.0497 | 1.18 | 1.21 | 6.63 | -- | 6.62 | -73.43 | 7.70 | -84.32 | 95.55 | -- | 5.59 | -383.28 | 7.75 | 1.87 | 1.05 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| ProQR Therapeutics NV | 20.88m | -24.04m | 145.39m | 157.00 | -- | 4.09 | -- | 6.96 | -0.2956 | -0.2956 | 0.2566 | 0.4352 | 0.1406 | -- | -- | 132,979.00 | -15.98 | -35.51 | -20.63 | -40.51 | -- | -- | -113.62 | -926.31 | -- | -- | 0.3687 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Invivyd Inc | 2.26m | -203.84m | 145.72m | 94.00 | -- | 1.04 | -- | 64.36 | -1.80 | -1.80 | 0.0199 | 1.18 | 0.0092 | -- | 1.13 | 24,085.11 | -82.73 | -- | -96.25 | -- | 96.11 | -- | -9,003.40 | -- | 4.57 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Repare Therapeutics Inc | 68.68m | -68.52m | 148.56m | 179.00 | -- | 0.7294 | -- | 2.16 | -1.63 | -1.63 | 1.61 | 4.80 | 0.2558 | -- | 6.34 | 383,703.90 | -25.52 | -23.40 | -30.30 | -26.37 | -- | -- | -99.76 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Quantum-Si Inc | 1.70m | -89.35m | 150.90m | 159.00 | -- | 0.6467 | -- | 88.66 | -0.6302 | -0.6302 | 0.012 | 1.64 | 0.0057 | 0.2321 | 3.68 | 10,704.40 | -29.89 | -- | -30.99 | -- | 53.41 | -- | -5,249.65 | -- | 20.13 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -64.86m | 155.01m | 51.00 | -- | 0.6354 | -- | -- | -1.11 | -1.11 | 0.00 | 4.06 | 0.00 | -- | -- | 0.00 | -27.82 | -- | -29.32 | -- | -- | -- | -- | -- | -- | -- | 0.1075 | -- | -- | -- | -22.20 | -- | -- | -- |
| Adverum Biotechnologies Inc | 0.00 | -99.86m | 156.01m | 121.00 | -- | 0.9285 | -- | -- | -7.99 | -7.99 | 0.00 | 8.08 | 0.00 | -- | -- | 0.00 | -40.33 | -36.39 | -46.64 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Actuate Therapeutics Inc | 0.00 | -27.77m | 156.52m | 6.00 | -- | -- | -- | -- | -1.45 | -1.45 | 0.00 | -0.7114 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -134.25 | -- | -- | -- | -- | -22.74 | -- | -- | -- |
| Achieve Life Sciences Inc | 0.00 | -27.54m | 156.60m | 22.00 | -- | 3.70 | -- | -- | -1.10 | -1.10 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -58.78 | -86.31 | -71.94 | -119.59 | -- | -- | -- | -- | -- | -11.79 | 0.294 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| P3 Health Partners Inc | 1.40bn | -69.48m | 159.51m | 400.00 | -- | 0.4323 | -- | 0.1137 | -0.5821 | -0.5821 | 11.56 | 1.03 | 1.56 | -- | 10.97 | 3,507,143.00 | -20.51 | -- | -110.70 | -- | 0.6223 | 0.1781 | -13.17 | -56.93 | -- | -9.67 | 0.2686 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Seres Therapeutics Inc | 374.00k | -162.11m | 160.00m | 233.00 | -- | -- | -- | 427.81 | -1.18 | -1.18 | 0.0027 | -0.5742 | 0.001 | -- | 0.0286 | 1,605.15 | -44.53 | -41.51 | -59.82 | -54.13 | -- | -- | -43,343.58 | -170.14 | 0.889 | -17.64 | 6.65 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Capricor Therapeutics Inc | 27.15m | -27.95m | 162.37m | 101.00 | -- | 13.88 | -- | 5.98 | -0.9302 | -0.9302 | 0.9072 | 0.3596 | 0.6443 | -- | 59.18 | 268,833.90 | -66.31 | -54.12 | -208.71 | -75.13 | -- | -- | -102.93 | -316.25 | -- | -- | 0.2269 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Skye Bioscience Inc | 0.00 | -42.29m | 166.56m | 11.00 | -- | 2.12 | -- | -- | -3.91 | -3.91 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -94.50 | -232.67 | -129.40 | -- | -- | -- | -- | -- | -- | -323.10 | 0.0626 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Context Therapeutics Inc | 0.00 | -18.57m | 167.25m | 5.00 | -- | 1.65 | -- | -- | -1.06 | -1.06 | 0.00 | 1.35 | 0.00 | -- | -- | 0.00 | -28.46 | -- | -29.68 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to Adverum Biotechnologies Inc's reporting currency: US Dollar USD
44.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 30 Jul 2024 | 2.27m | 10.90% |
| Franklin Advisers, Inc.as of 30 Jun 2024 | 1.76m | 8.46% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.27m | 6.08% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 992.42k | 4.77% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 637.51k | 3.07% |
| Assenagon Asset Management SA (Germany)as of 30 Jun 2024 | 617.91k | 2.97% |
| Geode Capital Management LLCas of 30 Jun 2024 | 455.79k | 2.19% |
| Avoro Capital Advisor LLCas of 30 Jun 2024 | 416.67k | 2.00% |
| Logos Global Management LPas of 30 Jun 2024 | 416.67k | 2.00% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 396.93k | 1.91% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
